- Odyssey Health ( OTCPK:ODYY ) said it launched a concept phase to develop an intra-nasal field-deliverable nerve agent antidote.
- Nerve agents kill brain cells causing respiratory failure, seizures, and death within minutes of exposure, the company added.
- The breath-propelled intranasal device is lightweight. The drug-device combination is being developed to increase brain drug exposure in minutes, according to the company.
- Odyssey noted that oximes are an antidote for organophosphate nerve agents but the current use is through a skin auto-injector.
- Odyssey said that the novel Oxime-Intranasal combination include almost immediate exposure of the central nervous system, enhanced brain cell protection with less drug required given the targeted approach.
For further details see:
Odyssey Health to develop intranasal nerve agent antidote